In the article that accompanies this editorial, Rahman et al 2 describe the results from the first three experimental arms of the INSIGhT trial which, to our knowledge, is the first adaptive platform ...

Randomization have proven to be an efficient way of reducing bias and thus is widely used in clinical trials. Randomization ensures that subject allocation is balanced across treatment group and is ...

A breast cancer screening study that pairs oncology therapies with biological markers (biomarkers) launched by a consortium of public health agencies, academics and companies is being heralded as a ...

Boston – An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments ...

Response-adaptive designs allow the randomization probabilities to change during the course of a trial based on cumulated response data so that a greater proportion of patients can be allocated to the ...

An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for ...

AUSTIN, Texas--(BUSINESS WIRE)--Berry Consultants, LLC announced today that it is discontinuing its involvement in the I-SPY trials in neoadjuvant breast cancer. Beginning in 2009, Donald Berry, PhD, ...